Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025
Provided By GlobeNewswire
Last update: Apr 24, 2025
– Expands Development Portfolio with Introduction of a Novel Program Targeting PSC –
– Confirms Highly Specific Allosteric ACLY Inhibitor Shown to Reduce Liver Injury, Inflammation and Fibrosis Across Multiple PSC-Relevant Pre-Clinical Models –
Read more at globenewswire.com
